Carlos Spuch

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6779339/publications.pdf

Version: 2024-02-01

67 papers	2,412 citations	236925 25 h-index	206112 48 g-index
76 all docs	76 docs citations	76 times ranked	4054 citing authors

#	Article	IF	Citations
1	Changes in the Brain Extracellular Matrix Composition in schizophrenia: A Pathophysiological Dysregulation and a Potential Therapeutic Target. Cellular and Molecular Neurobiology, 2022, 42, 1921-1932.	3.3	9
2	Efficacy and Safety of Lithium Treatment in SARS-CoV-2 Infected Patients. Frontiers in Pharmacology, 2022, 13, 850583.	3.5	4
3	Efficacy of the Therapeutic Game â€œTrisquelâ€•in the Treatment of Patients With Substance-Related Disorders Randomized Clinical Study. Frontiers in Psychiatry, 2022, 13, 864511.	2.6	0
4	Important role of microglia in HIV-1 associated neurocognitive disorders and the molecular pathways implicated in its pathogenesis. Annals of Medicine, 2021, 53, 43-69.	3.8	67
5	Perfil proteÃ³mico y metabÃ³lico de pacientes crÃ³nicos con esquizofrenia tras un programa de actividad fÃsica: estudio piloto. Revista De PsiquiatrÃa Y Salud Mental, 2021, 14, 125-138.	1.8	0
6	Proteomic and metabolic profiling of chronic patients with schizophrenia induced by a physical activity program: Pilot study. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2021, 14, 125-138.	0.3	2
7	The Role of the Second Extracellular Loop of Norepinephrine Transporter, Neurotrophin-3 and Tropomyosin Receptor Kinase C in T Cells: A Peripheral Biomarker in the Etiology of Schizophrenia. International Journal of Molecular Sciences, 2021, 22, 8499.	4.1	3
8	Cognitive Frailty: An Update. Frontiers in Psychology, 2021, 12, 813398.	2.1	21
9	Voices 2: Improving Prosodic Recognition in Schizophrenia With an Online Rehabilitation Program. Frontiers in Psychology, 2021, 12, 739252.	2.1	1
10	Brainwaves Oscillations as a Potential Biomarker for Major Depression Disorder Risk. Clinical EEG and Neuroscience, 2020, 51, 3-9.	1.7	33
11	A Systematic Review of Efficacy, Safety, and Tolerability of Duloxetine. Frontiers in Psychiatry, 2020, 11, 554899.	2.6	26
12	Does Lithium Deserve a Place in the Treatment Against COVID-19? A Preliminary Observational Study in Six Patients, Case Report. Frontiers in Pharmacology, 2020, 11, 557629.	3.5	23
13	Plasma Î²-III tubulin, neurofilament light chain and glial fibrillary acidic protein are associated with neurodegeneration and progression in schizophrenia. Scientific Reports, 2020, 10, 14271.	3.3	20
14	Annexin A5 prevents amyloid-Î²-induced toxicity in choroid plexus: implication for Alzheimerâ€™s disease. Scientific Reports, 2020, 10, 9391.	3.3	18
15	Mania as Debut of Cushingâ€™s Syndrome. Case Reports in Psychiatry, 2020, 2020, 1-3.	0.5	1
16	Effectiveness of the “Trisquel” board game intervention program for patients with schizophrenia spectrum disorders. Actas Espanolas De Psiquiatria, 2020, 48, 209-219.	0.1	1
17	Proteomics in Schizophrenia: A Gateway to Discover Potential Biomarkers of Psychoneuroimmune Pathways. Frontiers in Psychiatry, 2019, 10, 885.	2.6	18
18	Perfil neuropsicolÃ³gico y sintomatologÃa psicopatolÃ³gica de pacientes con trastornos relacionados con sustancias a tratamiento en una unidad de dÃa. Health and Addictions / Salud Y Drogas, 2019, 19, 70-79.	0.2	0

#	Article	IF	Citations
19	The role of the gut microbiota in schizophrenia: Current and future perspectives. World Journal of Biological Psychiatry, 2018, 19, 571-585.	2.6	39
20	The neurobiological hypothesis of neurotrophins in the pathophysiology of schizophrenia: A meta-analysis. Journal of Psychiatric Research, 2018, 106, 43-53.	3.1	40
21	P1â€533: DO BIOMARKERS DIFFERENTIATE COGNITIVE PROFILES IN MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER'S DISEASE?. Alzheimer's and Dementia, 2018, 14, P536.	0.8	0
22	Cytokines dysregulation in schizophrenia: A systematic review of psychoneuroimmune relationship. Schizophrenia Research, 2018, 197, 19-33.	2.0	77
23	Schizophrenia: A review of potential biomarkers. Journal of Psychiatric Research, 2017, 93, 37-49.	3.1	44
24	Epistasis, physical capacity-related genes and exceptional longevity: FNDC5 gene interactions with candidate genes FOXOA3 and APOE. BMC Genomics, 2017, 18, 803.	2.8	19
25	Soluble Megalin is Reduced in Cerebrospinal Fluid Samples of Alzheimerâ€™s Disease Patients. Frontiers in Cellular Neuroscience, 2015, 9, 134.	3.7	16
26	Treatment of Lysosomal Storage Diseases: Recent Patents and Future Strategies. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2014, 8, 9-25.	0.6	43
27	Loss of GABAergic cortical neurons underlies the neuropathology of Lafora disease. Molecular Brain, 2014, 7, 7.	2.6	44
28	Neurogenic effects of Î²-amyloid in the choroid plexus epithelial cells in Alzheimerâ€™s disease. Cellular and Molecular Life Sciences, 2013, 70, 2787-2797.	5.4	17
29	tPA in the Central Nervous System: Relations Between tPA and Cell Surface LRPs. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2013, 7, 65-76.	0.6	15
30	tPA in the central nervous system: relations between tPA and cell surface LRPs. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2013, 7, 65-76.	0.6	6
31	LRP-1 and LRP-2 receptors function in the membrane neuron. Trafficking mechanisms and proteolytic processing in Alzheimer's disease. Frontiers in Physiology, 2012, 3, 269.	2.8	86
32	Lafora Progressive Myoclonus Epilepsy: Recent Insights into Cell Degeneration. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2012, 6, 99-107.	0.6	5
33	Present and Future of Adeno Associated Virus Based Gene Therapy Approaches. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2012, 6, 47-66.	0.6	32
34	New Insights in the Amyloid-Beta Interaction with Mitochondria. Journal of Aging Research, 2012, 2012, 1-9.	0.9	86
35	Advances in the Treatment of Neurodegenerative Disorders Employing Nanoparticles. Recent Patents on Drug Delivery and Formulation, 2012, 6, 2-18.	2.1	71
36	Effects of a tacrine-8-hydroxyquinoline hybrid (IQM-622) on AÎ² accumulation and cell death: Involvement in hippocampal neuronal loss in Alzheimer's disease. Neurobiology of Disease, 2012, 46, 682-691.	4.4	42

#	Article	IF	Citations
37	Prolonged oral cannabinoid administration prevents neuroinflammation, lowers Î²-amyloid levels and improves cognitive performance in Tg APP 2576 mice. Journal of Neuroinflammation, 2012, 9, 8.	7.2	196
38	tPA in the Central Nervous System: Relations Between tPA and Cell Surface LRPs. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2012, 7, 65-76.	0.6	1
39	Leptin Induces Proliferation of Neuronal Progenitors and Neuroprotection in a Mouse Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 24, 17-25.	2.6	97
40	The p75 neurotrophin receptor localization in blood-CSF barrier: expression in choroid plexus epithelium. BMC Neuroscience, 2011, 12, 39.	1.9	15
41	New Insights in Prolactin Releasing Peptide (Prrp) in the Brain. Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 2011, 11, 228-233.	0.5	1
42	Liposomes for Targeted Delivery of Active Agents against Neurodegenerative Diseases (Alzheimer's) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	2.5	123
43	Hyperphagia and Central Mechanisms for Leptin Resistance during Pregnancy. Endocrinology, 2011, 152, 1355-1365.	2.8	69
44	Cell Microencapsulation Implants into the Central Nervous System. Recent Patents on Nanomedicine, 2011, 1, 60-67.	0.5	2
45	Hyperphagia and Central Mechanisms for Leptin Resistance during Pregnancy. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 869-869.	3.6	1
46	Cell Microencapsulation Implants into the Central Nervous System. Recent Patents on Nanomedicine, 2011, 1, 60-67.	0.5	0
47	Expression and Functions of LRP-2 in Central Nervous System: Progress in Understanding its Regulation and the Potential Use for Treatment of Neurodegenerative Diseases. Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 2010, 10, 249-254.	0.5	4
48	A New Tacrineâ€“Melatonin Hybrid Reduces Amyloid Burden and Behavioral Deficits in a Mouse Model of Alzheimerâ€™s Disease. Neurotoxicity Research, 2010, 17, 421-431.	2.7	59
49	The effect of encapsulated VEGF-secreting cells on brain amyloid load and behavioral impairment in a mouse model of Alzheimerâ€™s disease. Biomaterials, 2010, 31, 5608-5618.	11.4	114
50	Gelsolin Restores A<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>Î²</mml:mi></mml:math>-Induced Alterations in Choroid Plexus Epithelium. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-7.	3.0	19
51	The Therapeutic Potential of Microencapsulate Implants: Patents and Clinical Trials. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2010, 4, 59-68.	0.6	5
52	Megalin interacts with APP and the intracellular adapter protein FE65 in neurons. Molecular and Cellular Neurosciences, 2010, 45, 306-315.	2.2	57
53	AÎ² accumulation in choroid plexus is associated with mitochondrial-induced apoptosis. Neurobiology of Aging, 2010, 31, 1569-1581.	3.1	63
54	Transport Mechanisms at the Blood-Cerebrospinal-Fluid Barrier: Role of Megalin (LRP2). Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2010, 4, 190-205.	0.6	11

#	Article	IF	Citations
55	Ligand-independent signaling by disulfide-crosslinked dimers of the p75 neurotrophin receptor. Journal of Cell Science, 2009, 122, 3351-3357.	2.0	54
56	Cytoplasmic gelsolin increases mitochondrial activity and reduces AÎ² burden in a mouse model of Alzheimer's disease. Neurobiology of Disease, 2009, 36, 42-50.	4.4	64
57	Induction of angiogenesis by implantation of encapsulated cells expressing vegf: A new therapy approach on Alzheimer's disease?. Journal of the Neurological Sciences, 2009, 283, 260.	0.6	0
58	Protection by gelsolin on amyloid-b-induced toxicity in the blood-CSF-brain barrier: Apoptotic pathways. Journal of the Neurological Sciences, 2009, 283, 299.	0.6	0
59	Megalin mediates the transport of leptin across the blood-CSF barrier. Neurobiology of Aging, 2008, 29, 902-912.	3.1	170
60	Ghrelin improves growth hormone responses to growth hormone-releasing hormone in a streptozotocin-diabetic model of delayed onset. Journal of Endocrinological Investigation, 2007, 30, 298-305.	3.3	4
61	Prolactin-releasing peptide (PrRP) increases prolactin responses to TRH inÂvitro and inÂvivo. Endocrine, 2007, 31, 119-124.	2.3	7
62	Blockade of the insulin-like growth factor I receptor in the choroid plexus originates Alzheimer's-like neuropathology in rodents: New cues into the human disease?. Neurobiology of Aging, 2006, 27, 1618-1631.	3.1	129
63	Fibroblast Growth Factor-2 and Epidermal Growth Factor Modulate Prolactin Responses to TRH and Dopamine in Primary Cultures. Endocrine, 2006, 29, 317-324.	2.2	12
64	Choroid Plexus Megalin Is Involved in Neuroprotection by Serum Insulin-Like Growth Factor I. Journal of Neuroscience, 2005, 25, 10884-10893.	3.6	190
65	Heparin Increases Prolactin and Modifies the Effects of FGF-2 Upon Prolactin Accumulation in Pituitary Primary Cultures. Endocrine, 2004, 24, 131-136.	2.2	3
66	GH responses to GHRH and GHRP-6 in Streptozotocin (STZ)-diabetic rats. Life Sciences, 2003, 73, 3375-3385.	4.3	8
67	The Therapeutic Potential of Cell Encapsulation Technology for Drug Delivery in Neurological Disorders. , 0, , .		2